Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLQ3PO)

Drug Name

INCB13739 Drug Info

Synonyms

Phenylarsine oxide; phenylarsine oxide; Oxophenylarsine; 637-03-6; Arzene; Phenylarsenoxide; Arsenosobenzene; ARSINE, OXOPHENYL-; Phenyl arsine oxide; Benzene, arsenoso-; arsorosobenzene; Fenylarsinoxid; Caswell No 060; Fenylarsinoxid [Czech]; C6H5AsO; Phenyl arsenoxide; UNII-0HUR2WY345; PAO; EINECS 211-275-3; NSC 42470; EPA Pesticide Chemical Code 007101; BRN 2935227; 0HUR2WY345; CHEBI:75253; MFCD00001990; Phenylarsine oxide, 97%; Phenylarsine Oxide Solution; oxo(phenyl)arsan; Phenylarsinoxyd; oxo(phenyl)arsine; oxo(phenyl)arsane; PhAsO; phenylarsenious

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 2a	[1]
Diabetic complication	5A2Y	Phase 2	[1]

Cross-matching ID

PubChem CID: 11502183
TTD Drug ID: DMLQ3PO

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	TTN7BL9	DHI1_HUMAN	Inhibitor	[2]
Protein tyrosine phosphatase (PTP)	TTWC6MY	NOUNIPROTAC	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	DTT	HSD11B1	10.967	5.178	5.865	6.377

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Type-2 diabetes

ICD Disease Classification

5A11

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	DTT	HSD11B1	2.03E-01	-0.01	-0.08

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT00698230) Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics. U.S. National Institutes of Health.
2	Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
3	Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9.